Home > Insider Trading > Filing (0001062993-22-019586)

Filing Details

Accession Number:: 0001062993-22-019586
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-09-15 18:53:10
Reporting Period:: 2022-09-13

Accepted Time:: 2022-09-15 18:53:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659352	Codiak Biosciences Inc.	CDAK	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219039	Keith Crandell	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219042	Robert Nelsen	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219043	Clinton Bybee	8755 W. Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1605598	Arch Venture Fund Viii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1616165	Arch Venture Partners Viii, Llc	8755 West Higgins Road, Suite 1025 Chicago IL 606031	No	No	Yes	No
1616176	Arch Venture Partners Viii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1617237	Arch Venture Fund Viii Overage, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Sotck	Acquisiton	2022-09-13	5,000,000	$1.50	8,854,098	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (Right to Buy)	Acquisiton	2022-09-13	5,000,000	$0.00	5,000,000	$1.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,000,000	2022-09-13	2027-09-13	No	4	P	Direct

Footnotes

Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share.
Comprised of 7,503,903 shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII") and 1,350,195 shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage").
Shares and warrants held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
Shares held by ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.